• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Pharmacy Affairs
  • Newsletter

  • Overview
  • Product Sites
  • Pharmacy Assoc. and Conferences
  • Resources
  • Education for Pharmacists
  • Emerging Science
  • Newsletter
Amgen Pharmacy Affairs Newsletter

Amgen Pharmacy Affairs newsletter is published on a semi-annual basis and is a source for important information for the pharmacist community.

Current Newsletter

  • The Medicare Prescription Drug, Improvement and Modernization Act of 2003
  • Implication of Medicare Part D for Retail and Community Pharmacists
  • The Retail Pharmacist's Role in Facilitating Access to Medications for Uninsured or Underinsured Patient
  • More

Archived Newsletters

Coming soon.

  • Prescribing Information
  • Aranesp® (darbepoetin alfa) Prescribing Information
  • Enbrel® (etanercept) Prescribing Information
  • EPOGEN® (Epoetin alfa) Prescribing Information
  • Kepivance® (palifermin) Prescribing Information
  • Kineret® (anakinra) Prescribing Information
  • Neulasta® (pegfilgrastim) Prescribing Information
  • NEUPOGEN® (Filgrastim) Prescribing Information
  • Sensipar® (cinacalcet HCl) Prescribing Information
  • Vectibix® (panitumumab) Prescribing Information
  • Related Links
  • AmgenOncology.com
footer